| Primary |
| Carcinoid Tumour |
23.2% |
| Acromegaly |
22.7% |
| Neuroendocrine Tumour |
15.7% |
| Carcinoid Syndrome |
8.8% |
| Metastatic Carcinoid Tumour |
5.9% |
| Pancreatic Neuroendocrine Tumour |
5.2% |
| Neuroendocrine Carcinoma |
3.3% |
| Hypertension |
2.5% |
| Diarrhoea |
1.7% |
| Pancreatic Carcinoma |
1.5% |
| Diabetes Mellitus |
1.1% |
| Hepatic Neoplasm Malignant |
1.1% |
| Pain |
1.0% |
| Pituitary Tumour |
1.0% |
| Blood Pressure Abnormal |
0.9% |
| Angiodysplasia |
0.9% |
| Vipoma |
0.9% |
| Osteoporosis |
0.8% |
| Small Intestine Carcinoma |
0.8% |
| Pancreatitis Chronic |
0.8% |
|
| Death |
22.1% |
| Weight Decreased |
15.3% |
| Vomiting |
9.9% |
| Diarrhoea |
6.0% |
| Pain |
4.5% |
| Nausea |
4.5% |
| Fatigue |
3.8% |
| Malaise |
3.5% |
| Weight Increased |
3.0% |
| Blood Pressure Systolic Increased |
2.8% |
| Blood Pressure Increased |
2.8% |
| Pyrexia |
2.8% |
| Neoplasm Malignant |
2.7% |
| Dyspnoea |
2.6% |
| Injection Site Pain |
2.5% |
| Oedema Peripheral |
2.4% |
| Urinary Tract Infection |
2.4% |
| Terminal State |
2.2% |
| Heart Rate Increased |
2.1% |
| Asthenia |
2.1% |
|
| Secondary |
| Carcinoid Tumour |
23.2% |
| Neuroendocrine Tumour |
17.2% |
| Acromegaly |
14.7% |
| Carcinoid Syndrome |
10.7% |
| Metastatic Carcinoid Tumour |
7.2% |
| Pancreatic Neuroendocrine Tumour |
4.5% |
| Carcinoid Tumour Of The Gastrointestinal Tract |
3.2% |
| Neuroendocrine Carcinoma |
3.1% |
| Hypertension |
2.6% |
| Blood Pressure Abnormal |
2.1% |
| Small Intestine Carcinoma |
1.4% |
| Short-bowel Syndrome |
1.3% |
| Diabetes Mellitus |
1.2% |
| Pituitary Tumour Benign |
1.2% |
| Gastrinoma |
1.2% |
| Pain |
1.2% |
| Diarrhoea |
1.0% |
| Crohn's Disease |
1.0% |
| Carcinoid Tumour Of The Small Bowel |
0.9% |
| Vipoma |
0.9% |
|
| Weight Decreased |
15.8% |
| Vomiting |
11.9% |
| Diarrhoea |
8.0% |
| Fatigue |
6.9% |
| Death |
6.2% |
| Nausea |
5.0% |
| Injection Site Pain |
4.9% |
| Blood Pressure Increased |
4.5% |
| Flatulence |
3.8% |
| Blood Pressure Systolic Increased |
3.7% |
| Headache |
3.6% |
| Abdominal Pain |
3.6% |
| Malaise |
3.2% |
| Pain |
3.0% |
| Oedema Peripheral |
2.9% |
| Weight Increased |
2.8% |
| Neoplasm Malignant |
2.7% |
| Asthenia |
2.6% |
| Dyspnoea |
2.6% |
| Nasopharyngitis |
2.4% |
|
| Concomitant |
| Carcinoid Tumour |
18.3% |
| Pancreatic Neuroendocrine Tumour |
15.2% |
| Hypertension |
10.5% |
| Pain |
6.3% |
| Neuroendocrine Tumour |
5.2% |
| Drug Use For Unknown Indication |
4.9% |
| Diarrhoea |
4.7% |
| Depression |
4.0% |
| Emphysema |
4.0% |
| Pain Management |
4.0% |
| Asthenopia |
3.7% |
| Diabetes Mellitus |
3.4% |
| Acromegaly |
2.9% |
| Neuroendocrine Carcinoma |
2.6% |
| Product Used For Unknown Indication |
2.3% |
| Hypothyroidism |
1.7% |
| Headache |
1.6% |
| Hypoparathyroidism |
1.6% |
| Metastases To Bone |
1.6% |
| Pancreatic Neoplasm |
1.6% |
|
| Weight Decreased |
30.9% |
| Vomiting |
8.2% |
| Venous Occlusion |
5.5% |
| Sepsis |
4.5% |
| Syncope |
4.5% |
| Urticaria |
4.5% |
| Gastritis Erosive |
3.6% |
| Oedema Peripheral |
3.6% |
| Pruritus |
3.6% |
| Weight Increased |
3.6% |
| Blood Bilirubin Increased |
2.7% |
| Circulatory Collapse |
2.7% |
| Disease Progression |
2.7% |
| Haematuria |
2.7% |
| Liver Function Test Abnormal |
2.7% |
| Neoplasm Malignant |
2.7% |
| Respiratory Depression |
2.7% |
| Stomatitis |
2.7% |
| Urinary Tract Infection |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
|
| Interacting |
| Neuroendocrine Tumour |
64.3% |
| Pancreatic Neuroendocrine Tumour Metastatic |
14.3% |
| Heart Rate Irregular |
7.1% |
| Lung Neoplasm Malignant |
7.1% |
| Thymoma |
7.1% |
|
| Drug Interaction |
28.6% |
| Cholelithiasis |
14.3% |
| Dyspnoea |
14.3% |
| Blood Pressure Systolic Increased |
7.1% |
| Bradycardia |
7.1% |
| Dysstasia |
7.1% |
| International Normalised Ratio Increased |
7.1% |
| Urinary Tract Infection |
7.1% |
| Weight Increased |
7.1% |
|
